Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of albumin-bound docetaxel injection in previously treated pancreatic cancer
CTR20222900Phase 2Active
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jan 2023
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of albumin-bound docetaxel in pancreatic cancer (PC), pancreatic adenocarcinoma (PDAC), sponsored by CSPC ZhongQi Pharmaceutical Technology. Started Jan 2023; status: active.
02
Drugs
albumin-bound docetaxel
03
Conditions
pancreatic cancer (PC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on CTR20222900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222900.